COO
ONL Therapeutics
Connie Chang has 25+ years of experience in life sciences spanning large pharma, small
pharma and biomedical technology commercialization. She is currently Chief Operating Officer
of ONL Therapeutics, a clinical stage biopharma company developing novel therapies to treat
blinding diseases of the eye, including retinal detachment, age-related macular degeneration
and glaucoma. In this role she is responsible business functions including regulatory, corporate
strategy, finance, HR, legal, quality management and communications
Previously, Connie was Vice President of Corporate Affairs at Millendo Therapeutics responsible
for building critical infrastructure as the company became publicly traded and integrating
global company operations. She served as the inaugural managing director of the
commercialization and entrepreneurship unit of the University of Michigan Medical School
Office of Research, supporting faculty members engaged in translational biomedical research.
At Sepracor, Connie was Senior Director and brand team leader for the sleep and respiratory
business units, and earlier in her career at Pfizer, she worked on commercial teams in allergy,
cardiovascular and CNS.
Connie continues to provide leadership and guidance to research institutes and faculty working
in translational research, serving as a trustee for the Van Andel Institute and on the operating
committee for the Michigan Pittsburgh Wyss Regenerative Medicine Resource Center, an NIH-
funded partnership between the University of Michigan, the University of Pittsburgh, and the
Wyss Institute at Harvard.
Connie received her Bachelor of Arts degree in psychobiology from Harvard University,
graduating magna cum laude and Phi Beta Kappa, and an MBA from Harvard Business School.
She and her husband have two daughters and reside in Ann Arbor, Michigan.
